1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734–739.
2. Haas DW, Seekins D, Cooper R, et al.: A phase II, doubleblind, placebo-controlled, dose ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, SustivaTM, DMP 266) in combination with open-label zidovudine (ZDV) with lamivudine (3tc) at 36 weeks [DMP 266-005] [abstract]. In Program and Abstracts of the 12th World AIDS Conference. Geneva, Switzerland 1998:22334.
3. Deeks S, Loftus R, Cohen P, et al.: Incidence and predictors of virologic failure to indinavir (IDV) and/or ritonavir (RTV) in an urban health clinic [abstract]. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997:LB-2.
4. Moore RD, Keruly JC, Chaisson RE: Effectiveness of combination antiretroviral therapy in clinical practice [abstract]. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 1997:I–181.
5. Department of Health and Human Services and the Henry J. Kaiser Family Foundation: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 128:1079–1100. A discussion of “adherence to potent antiretroviral therapy” is available as a supplement to the guidelines for the “treatment of HIV infected adult and adolescents” on AIDS Treatment Information Service website at http://www.hivatis.org/trtgdlns.html.